Arne Materna

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Bruker announced that it has hired Gerald Herman as its new CFO. He replaces Anthony Mattacchione, whose resignation was announced in February. Herman joined Bruker in 2016 as VP and corporate controller, and has been serving as interim CFO since March 2018. He previously served a corporate VP - Clinical Operations of Parexel International from 2014 to February 2016, and as corporate VP and controller-finance of Parexel from 2008 to 2013. Prior to 2008, he was VP - corporate controller of Presstek.

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, scientific program director of computational health at the University of California, San Francisco, is leading development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously was vice president of developer tools at Apple and an e-commerce hardware developer for Sun Microsystems. 

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.

Michael Sanderson has been appointed CEO of PierianDx and director of the company's board. Sanderson has more than 25 years in the healthcare industry, mostly in healthcare analytics and big data. Most recently he has been a consultant focused on health IT and analytics, according to his LinkedIn profile. He was previously president and cofounder of RemitData.